TEVETEN HCT Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Teveten Hct, and when can generic versions of Teveten Hct launch?

Teveten Hct is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in TEVETEN HCT is eprosartan mesylate; hydrochlorothiazide. There are eleven drug master file entries for this compound. Additional details are available on the eprosartan mesylate; hydrochlorothiazide profile page.

Summary for TEVETEN HCT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	3
Patent Applications:	8
Formulation / Manufacturing:	see details
What excipients (inactive ingredients) are in TEVETEN HCT?	TEVETEN HCT excipients list
DailyMed Link:	TEVETEN HCT at DailyMed

Drug patent expirations by year for TEVETEN HCT

Recent Clinical Trials for TEVETEN HCT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Synexus	Phase 3
Quintiles, Inc.	Phase 3
Abbott	Phase 3

See all TEVETEN HCT clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for TEVETEN HCT

C03AA	Thiazides, plain
C03A	LOW-CEILING DIURETICS, THIAZIDES
C03	DIURETICS
C	Cardiovascular system

C09CA	Angiotensin II receptor blockers (ARBs), plain
C09C	ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C	Cardiovascular system

US Patents and Regulatory Information for TEVETEN HCT

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	TEVETEN HCT	eprosartan mesylate; hydrochlorothiazide	TABLET;ORAL	021268-001	Nov 1, 2001		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Abbvie	TEVETEN HCT	eprosartan mesylate; hydrochlorothiazide	TABLET;ORAL	021268-002	Nov 1, 2001		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for TEVETEN HCT

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	TEVETEN HCT	eprosartan mesylate; hydrochlorothiazide	TABLET;ORAL	021268-002	Nov 1, 2001	⤷ Try a Trial	⤷ Try a Trial
Abbvie	TEVETEN HCT	eprosartan mesylate; hydrochlorothiazide	TABLET;ORAL	021268-002	Nov 1, 2001	⤷ Try a Trial	⤷ Try a Trial
Abbvie	TEVETEN HCT	eprosartan mesylate; hydrochlorothiazide	TABLET;ORAL	021268-001	Nov 1, 2001	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for TEVETEN HCT

See the table below for patents covering TEVETEN HCT around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Canada	2018443		⤷ Try a Trial
Bulgaria	98454		⤷ Try a Trial
Netherlands	300115		⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for TEVETEN HCT

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0565634	91234	Luxembourg	⤷ Try a Trial	91234, EXPIRES: 20161213
0565634	300115	Netherlands	⤷ Try a Trial
0565634	06C0030	France	⤷ Try a Trial	PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Summary for TEVETEN HCT

Recent Clinical Trials for TEVETEN HCT

Anatomical Therapeutic Chemical (ATC) Classes for TEVETEN HCT

Make Better Decisions: Try a trial or see plans & pricing